Antibody-Drug Conjugate (ADC) – From Bioassay Development To Linker-Payload Constructs

ADCs have emerged as a promising class of targeted cancer therapies. By combining the specificity of antibodies with the potency of cytotoxic drugs, they offer a more precise approach to treating cancer. The development of robust bioassays is essential for ensuring the efficacy and safety of ADCs. These assays allow for the evaluation of linker stability, drug release, and overall therapeutic activity.

In this webinar, we delve into Curia's experience in ADC discovery. We discuss key design elements, including linker types and payloads, as well as the conjugation and characterization of ADCs. Additionally, we explore the various bioassays used to screen ADCs, focusing on linker stability, internalization, drug release, and therapeutic activity.

Key Takeaways:

• Understand the different types of linkers and payloads used in ADCs.
• Learn about stochastic bioconjugation and discovery-scale ADC characterization.
• Explore the methodologies involved in developing robust bioassays for ADCs.

By understanding these concepts, we can contribute to the advancement of ADCs as effective cancer treatments.